In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Vosoritide | Synthetic fragment BPC-157 | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 306 | 987 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 90 (90 in people) | 24 (8 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 16 · 12 active | 3 · 2 active1 more mentions it but does not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Voxzogo says: “Pediatric achondroplasia with open epiphyses”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Vosoritide | BPC-157 |
|---|---|---|
| Bone and jointMusculoskeletal | 14113011 | 1414 |
| Adverse eventsWhole body |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 30 Oct 2026).
6969
24816 |
| Receptor activity and mechanismPharmacology | 15132 | 805129 |
|---|
| Heart functionCardiovascular | 11 | 5656 |
|---|
| PharmacokineticsPharmacology | 15123 | 871 |
|---|
| Exercise and physical functionMusculoskeletal | 99 | 1010 |
|---|
| MortalityWhole body | 66 | 1414 |
|---|
| Blood pressureCardiovascular | 22 | 2323 |
|---|
| Growth hormone and IGF-1Endocrine and hormones | 66 | 11 |
|---|
| Body weightMetabolic and weight | 33 | 66 |
|---|
| Vision and retinaEye | 44 | 22 |
|---|
| Immune responseImmune and inflammation | 11 | 66 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Vosoritide | BPC-157 |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: difference from placebo, in cm/year | 1.57 cm/year Adjusted mean difference in annualized growth velocity Dose studied: 15 μg/kg once daily52 weeksn = 1212020 | No randomized trial result 14 results from other study designs. |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 87.8% At least one AE Placebo: 72.5% 52 weeksn = 812026 | No randomized trial result 24 results from other study designs. |
1.57 cm/year
Adjusted mean difference in annualized growth velocity
Dose studied: 15 μg/kg once daily52 weeksn = 1212020
No randomized trial result
14 results from other study designs.
87.8%
At least one AE
Placebo: 72.5%
52 weeksn = 812026
No randomized trial result
24 results from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 16 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
BioMarin Pharmaceutical121 participants12 Dec 2016 to 30 Oct 2019
Achondroplasia
BioMarin Pharmaceutical160 participants20 Apr 2026 to est. Sept 2029
Achondroplasia
BioMarin Pharmaceutical140 participants20 Jun 2025 to est. Oct 2044
Hypochondroplasia
3 trials · 1 ongoing · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)
Hudson Biotech120 participants2 Feb 2026 to est. 17 Feb 2028
Hamstring Muscle Strain · Skeletal Muscle Injury
PharmaCotherapia d.o.o.42 participantsOct 2015 to est. Mar 2016
Healthy Volunteers
University of Arkansas30 participantsest. 1 Jan 2027 to est. 1 Aug 2027
Rotator Cuff Tear
1 more mentions it but does not test it. They only measure it or name it in their text.